Breast cytology and biomarkers obtained by random fine needle aspiration: Use in risk assessment and early chemoprevention trials

Journal of Cellular Biochemistry

Volumn 67, Issue SUPPL. 28/29, 1997, Pages 101-110

  Fabian, Carol J ^a,c   Zalles, Carola ^a   Kamel, Sahar ^a   Zeiger, Sandy ^a   Simon, Connie ^a   Kimler, Bruce F ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

Biomarker; Breast; Breast cancer development; Chemoprevention; Clinical trials; Cytology; EGFR; ER; Fin needle aspiration; FNA; HER 2 neu; High risk; p53; Ploidy; Risk assessment; Surrogate endpoint

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLINE; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; PLACEBO; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ANEUPLOIDY; ARTICLE; ASPIRATION BIOPSY; ASPIRATION CYTOLOGY; BREAST CANCER; CANCER FAMILY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENE OVEREXPRESSION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRECANCER; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELATIVE; RISK ASSESSMENT; BREAST; BREAST TUMOR; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PILOT STUDY; PROSPECTIVE STUDY;

ADULT; AGED; BIOPSY, NEEDLE; BREAST; BREAST NEOPLASMS; CHEMOPREVENTION; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 0031401658     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(1997)28/29+<101::AID-JCB11>3.0.CO;2-K     Document Type: Article

References (21)

1. Morrow M, Jordan VC (1994): The prevention of breast cancer with tamoxifen. In Jordan VC (ed): "Long-term Tamoxifen Treatment for Breast Cancer." Madison: University of Wisconsin Press, pp 257-278.
2. Boccardo F, Amoroso D, Rubagotti A, Capellini M, Pacini P, Castagnetta L, Traina A, Farris A, Iacobelli S, Mustacchi G, Nenci I, Piffanelli A, Sismondi P, De Sanctus C, Mesiti M, Gallo L, Villa E, Schieppati G (1994): Prolonged tamoxifen treatment of early breast cancer: The Experience of the Italian Cooperative Group for Chemohormonal therapy of early breast cancer. In Jordan VC (ed): "Long-term Tamoxifen Treatment for Breast Cancer." Madison: University of Wisconsin Press, pp 159-179.
3. Houghton J, Riley D, Baum M (1994): The Nolvadex Adjuvant Trial Organization (NATO) and the Cancer Research Campaign (CRC) trials of adjuvant tamoxifen therapy. In Jordan VC (ed): "Long-term Tamoxifen Treatment for Breast Cancer." Madison: University of Wisconsin Press, pp 93-113.
4. Costa A, Decensi A, DePalo A, Veronesi G (1996): Breast cancer chemoprevention with retinoids and tamoxifen. Proc Am Assoc Cancer Res 37:655.
5. Mulshine J (1995): Fostering chemopreventive agent development: How to proceed? J Cell Biochem Suppl 22:254-259.
6. Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Doody LA, Greenwald P (1993): Development of breast cancer chemopreventive drugs. J Cell Biochem 17(Suppl G):2-13.
7. O'Shaugnessy JA (1996): Chemoprevention of breast cancer. JAMA 275:1349-1353.
8. Dhingra K (1995): A phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer. J Cell Biochem 23 (Suppl):19-24.
9. Marshall CJ, Schumann GB, Ward JH, Riding JM, Cannon-Albright L, Skolnick M (1991): Cytologic identification of clinically occult proliferative breast disease in women with a family history of breast cancer. Am J Clin Pathol 95:157-165.
10. Wrensch M, Petrakis NL, King EB, Lee MM, Miike R (1993): Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy. Am J Epidemiol 137:829-833.
11. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schair C, Mulvihill JJ (1989): Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886.
12. Fabian C, Zalles C, Kamel S, McKittrick R, Moore W, Zeiger S, Simon C, Kimler B, Cramer A, Garcia F, Jewell W (1993): Biomarker and cytologic abnormalities in women at high and low risk for breast cancer. J Cell Biochem 17 (Suppl G):153-160.
13. Fabian CJ, Kamel S, Kimler BF, McKittrick R (1995): Potential use of biomarkers in breast cancer risk assessment and chemoprevention trials. Breast J 1:236-242.
14. Fabian CJ, Kamel S, Zalles CM, Kimler BF (1996): Identification of a chemoprevention cohort from a population of women at high risk for breast cancer. J Cell Biochem 253:112-122.
15. Zalles C, Kimler BF, Kamel S, McKittrick R, Fabian CJ (1995): Cytologic patterns in random aspirates from women at high and low risk for breast cancer. Breast J 1:343-349.
16. Pearson ES (1970): "Biometrika Tables for Statisticians," 3rd ed, Vol. 1. Pearson ES, Hartley HO (eds). Cambridge, MA: Cambridge University Press.
17. Dillon WR, Goldstein M (1984): "Multivariate Analysis Methods and Application." New York: John Wiley and Sons.
18. Pedhazur EJ (1984): "Multiple Regression in Behavior Research," 2nd ed. New York: Holt, Rinehart and Winston.
19. Ford D, Easton DF, Peto J (1995): Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457-1462.
20. Horsfall DJ, Jarvis LR, Grimbaldeston MA, Tilley WD, Orell SR (1989): Immunocytochemical assay for estrogen receptor in fine needle aspirates of breast cancer by video image analysis. Br J Cancer 59:129-134.
21. Masood S, Frykberg ER, McLellan GL, Scalapino MC, Mitchum DG, Bullard JB (1990): Prospective evaluation of radiologically directed fine-needle aspiration biopsy of nonpalpable breast lesions. Cancer 66:1480-1487.